Group items tagged

This FOA invites Research and Development Center (P30) grant applications in demography, economics and health services research relevant to Alzheimer's Disease and Alzheimer's Related Dementias (AD/ADRD). Areas of focus that are especially encouraged are: a) national and international population trends in cognitive aging and AD/ADRD; b) demography of dementia care and caregiving; c) economic burden of AD/ADRD; d) impact of health care systems and long-term supports and services on outcomes for persons with dementia and their care providers; e) impact of health care financing policies on outcomes for persons with dementia and their care providers; f) how regulatory and economic incentives affect access, quality and health outcomes in health and long-term care systems for persons with dementia; g) disparities in quality and access to dementia care; h) effects of population-level health delivery and care interventions on outcomes of persons with dementia; and i) national and international projections of dementia caseload, incidence and prevalence. Center grant applications must include two mandatory Cores and may choose among three optional Cores. Centers are required to work collaboratively with the Coordinating Center to be funded via RFA-AG-20-003.  

This funding opportunity announcement (FOA) invites applications for the next five-year cycle of the National Health and Aging Trends Study (NHATS), the leading nationally representative, longitudinal data resource in the US for research on trends, dynamics, and disparities in late-life disability, and for studies of the social and economic consequences of late-life disability for individuals, families and society, including caregiving and end-of-life issues. NHATS has conducted seven annual rounds of data collection to date (an eighth round is in process) and is linked to the separately funded National Study of Caregiving (NSOC). The goals of the next cycle are to: 1) Continue the current structure and design elements of NHATS; 2) Permit studies of long-term trends in disability prevalence; 3) Enrich measurement of cognitive capacity; 4) Enhance measurement of physical activity and sedentary behavior; 5) Continue linkages with administrative records; and 6) Augment data dissemination and user support.

The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.

The goal of the interagency Smartand Connected Health (SCH): Connecting Data, People and Systems program is to accelerate the development and integration of innovative computer and information scienceand engineering approaches to support the transformation of health and medicine. Approaches that partner technology-based solutions with biomedical and biobehavioral research are supported by multiple agencies of the federal government including the National Science Foundation (NSF) and the National Institutes of Health (NIH). The purpose of this program is to develop next-generation multidisciplinary science that encourages existing and new research communities to focus on breakthrough ideas in a variety of areas of value to health, such as networking, pervasive computing, advanced analytics, sensor integration, privacy and security, modeling of socio-behavioral and cognitive processes and system and process modeling. Effective solutions must satisfy a multitude of constraints arising from clinical/medical needs, barriers to change, heterogeneity of data, semantic mismatch and limitations of current cyberphysical systems and an aging population.Such solutions demand multidisciplinary teams ready to address issues ranging from fundamental science and engineering to medical and public health practice.

The Brookdale Foundation Group works to advance the fields of geriatrics and gerontology and to improve the lives of senior citizens. The Brookdale National Group Respite Program awards seed grants to service providers that plan to offer new, dementia-specific Group Respite or specialized Early Memory Loss (EML) programming to participants, along with support to caregivers, in order to help individuals remain in their communities. All funded programs must provide a day program for people affected by Alzheimer's disease or other dementia, which is limited to those who are cognitively impaired. Grants of $10,000 will be provided in year one, renewable for $5,000 for the second year, based on evaluation of first year's activities and potential for future continuity of the program. The application deadline is June 27, 2018. Visit the Brookdale Foundation Group's website to download the guidelines and application form.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse on older patients cohorts.

This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD.

The goal of the interagency Smart and Connected Health (SCH): Connecting Data, People and Systems program is to accelerate the development and integration of innovative computer and information science and engineering approaches to support the transformation of health and medicine. Approaches that partner technology-based solutions with biomedical and biobehavioral research are supported by multiple agencies of the federal government including the National Science Foundation (NSF) and the National Institutes of Health (NIH). The purpose of this program is to develop next-generation multidisciplinary science that encourages existing and new research communities to focus on breakthrough ideas in a variety of areas of value to health, such as networking, pervasive computing, advanced analytics, sensor integration, privacy and security, modeling of socio-behavioral and cognitive processes and system and process modeling. Effective solutions must satisfy a multitude of constraints arising from clinical/medical needs, barriers to change, heterogeneity of data, semantic mismatch and limitations of current cyberphysical systems and an aging population. Such solutions demand multidisciplinary teams ready to address issues ranging from fundamental science and engineering to medical and public health practice.

The PRARP Quality of Life Research Award (QUAL) mechanism was first offered in FY13. Since then, 38 QUAL applications have been received, and 16 have been recommended for funding. The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD, and (2) reduce the burden of care on the caregiver for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent. Both are equally important. As part of the research strategy, all applications must include cognitive, neuropsychological, or otherwise appropriate measures. The FY17 PRARP QUAL is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. Applications should also address how all of the included study measures address the research strategy and the study's hypothesis or hypotheses. The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP QUAL will not exceed $500,000. The maximum period of performance is 3 years.

This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease, and related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and ADRD.

The goal of this FOA is to support short courses geared to behavioral and social scientists who have existing expertise in aging research and can make research contributions in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) with additional knowledge about the disease and related research resources. Fields of behavioral and social science research relevant for this FOA are health economics, labor economics, health services research, healthcare policy, public policy, demography, sociology, social epidemiology, psychology, and social neuroscience. Priority areas of focus include, but are not limited to, the following: dementia care; dementia caregiver research; cognitive and dementia epidemiology; behavioral and social pathways of AD/ADRD; role of social, contextual, environmental, and institutional factors in AD/ADRD; early psychological changes preceding AD/ADRD onset; prevention of AD/ADRD; disparities in AD/ADRD or dementia-related outcomes; and research resources and methods for studying the determinants and impact of AD/ADRD.

Studies have found that older adults who participate in what they see as meaningful activities, like volunteering in their community, reported feeling healthier and happier. Other studies have found that older adults who have a full social network and participate in many social activities tend to have less cognitive decline and a decreased risk of dementia than those who are not socially engaged do. The Administration on Aging is interested in increasing ACL and the Aging Network’s understanding of what constitutes good practice for promoting and supporting social engagement among older adult and expanding the reach of the Aging Network to more effectively serve older adults by providing tools and resources necessary for aging organizations to assist older adults to remain socially engaged and active.

As an administrative supplement, the work proposed needs to be within the scope of the research or training that is already supported. Center awards and resource awards are most likely to be able to justify these supplements as they tend to have a broad content scope. Some research grants will also qualify if the current research is on a related topic. Topics may include, but are not limited to, cognitive decline in aging, caregiving, or research on the biology of neurodegeneration. Research proposed in supplement applications should have clear relevance to ADRD. The proposed work may include pilot projects, resource development, or secondary analysis of existing data. In each case, the work proposed should be feasible to complete within a one-year timeframe and with the limited funds permitted. It should also show promise of becoming a more substantial project that might attract funding.

The intent of the research funded through this award is to (1) support research to alleviate, stabilize, or characterize the symptoms or deficits common to TBI and AD/ADRD, and (2) reduce the burden of care on the caregiver for individuals living with the common symptoms of TBI and AD/ADRD. Research may be proposed to either facet of the intent. Both are equally important. As part of the research strategy, all applications must include cognitive, neuropsychological, or otherwise appropriate measures.The FY17 PRARP QUAL is open to Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) from any field or discipline. As part of the application, the PI should demonstrate that the study team has experience in both TBI and AD/ADRD research. Preliminary data, while not required, are encouraged. Preliminary data may come from the PI's published work, pilot data, or from peer-reviewed literature. Applications should also address how all of the included study measures address the research strategy and the study's hypothesis or hypotheses.The anticipated direct costs budgeted for the entire period of performance for an FY17 PRARP QUAL will not exceed $500,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.The research impact is expected to benefit the military, Veteran, and civilian communities. To this end, the PRARP has identified QUAL Overarching Challenges and Focus Areas by which the intent of this mechanism can be facilitated. These should be carefully considered as part of the application process.FY17 PRARP QUAL Overarching Challenges: T

The National Institute on Aging is seeking applications on systems biology approaches using non-mammalian laboratory animal models to increase our understanding of the basic biology underpinning neurodegeneration. It is expected that research supported under this FOA will provide new insights into molecular networks that might be involved in causing, amplifying or protecting against neurodegeneration, and that, in turn, might ultimately contribute to Alzheimer's disease or related dementias. Importantly, a major goal of this FOA is to use interaction and regulatory networks produced and analyzed using systems biology to gain these new insights. Because this FOA is directed toward discovery, currently employed genetically modified laboratory animals used to study AD are not required, although they may be used. Because this FOA requires systems biology approaches, data used to build interaction or regulatory networks may also come from humans or other mammals in which AD, related dementias, or aging-related cognitive decline have been observed. This FOA will only support studies using non-mammalian laboratory animal models; studies involving humans or experiments with mammals will not be allowed under this FOA.

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains.  Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of, and develop effective treatments for, AD by 2025. As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-fy2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits and milestones published in the FY2017 Alzheimer's disease bypass budget to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD. 

This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the "ApoE2-Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/crosstalk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across all regions of the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of and develop effective treatments for AD by 2025.  As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-FY 2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.

The NIA Behavioral and Social Research LEaders in Alzheimer's Disease and Its Related Dementias (NIA BSR LEADR) program supports individual scientists of exceptional creativity who propose to use behavioral and social science perspectives and approaches for highly innovative, impactful, and potentially transformative theoretical, empirical, and clinical research addressing the challenges raised by Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) for individuals, their families, and society. Applications are welcome from individuals with diverse backgrounds. NIA encourages applications on a variety of AD/ADRD topics in which behavioral and social research can contribute, such as dementia care, dementia caregiver research, cognitive and dementia epidemiology, behavioral and social pathways of AD/ADRD, early psychological changes preceding AD/ADRD, prevention of AD/ADRD, and disparities in AD/ADRD or dementia-related outcomes.

The overall goal of this FOA is to support the development of a collaborative research and resource network to synergize the expertise, skills, and resources of investigators within the geriatric emergency medicine and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research communities to identify and address research gaps towards optimizing recognition and emergency care of older adults with AD/ADRD. Support is provided for up to 2 years of planning/development (R61 phase) of a milestone-driven infrastructure including the initial identification of top-priority research gaps and the establishment of strategies to address them. Areas identified as needing additional evidence-based research include, but are not limited to, pre-emergency department (ED) strategies to avoid non-emergency ED visits, recognition of early cognitive impairment in the ED, strategies to optimize the ED environment and providers for patients with AD/ADRD, development of safe disposition criteria, and methods to minimize system fragmentation within and across health and social services.